01/19/21 MiRagen Therapeutics, Inc. announced its name change to Viridian Therapeutics, Inc. (NASDAQ: VRDN). The Company also announced today the appointment of Jonathan Violin, Ph.D., M.B.A. as President and Chief Executive Officer and member of the Board of Directors.

10/01/20 The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with DEB. Evangelos Badiavas, MD, PhD, Chief Scientific Officer at Aegle Therapeutics said, “This designation will expedite the development and regulatory review of AGLE-102 and highlights the importance…